Manuel Hidalgo, MD/PhD
Johns Hopkins Cancer Center
Baltimore, Maryland
Dr. Manuel Hidalgo, M.D., Ph.D., is the Associate Professor
of Oncology at the Sidney Kimmel Comprehensive Cancer Center,
Johns Hopkins University School of Medicine and Director of the
Centro Integral Oncologia "Clara Campal" in Madrid, Spain. He
is considered a leading researcher in the field of targeted therapies
for the treatment of cancer in patients with solid tumors. His
research interest focuses on the development of novel anticancer
agents for patients with gastrointestinal cancer by measuring
target receptor and molecular anomalies, as well as analyzing
biological activity in the tumor and normal tissues of patients
treated with specific therapies.
Dr. Hidalgo has published over 140 papers in leading cancer journals as well as numerous chapters in major textbooks. He has received numerous awards including an AACR Young Investigator Award, an NCI-EORTC fellowship and an ASCO Career Development Award. He has served on the editorial board of the Journal of Clinical Oncology and Clinical Cancer Research and is a Senior Editor for Molecular Cancer Therapeutics. Dr. Hidalgo has chaired the AACR and ASCO Program Committee in developmental therapeutics on numerous occasions and is frequently invited to speak at major national and international meetings. He chairs the Pancreatic Cancer Research Team, a nonprofit organization focused on clinical trials in pancreatic cancer and is also a member of the NCI Developmental Therapeutics Study Section.
Michael Shattock, PhD
King's College of Medicine, St. Thomas Hospital, London, England
Professor Shattock is Professor of Cellular Cardiology and head
of Cardiac Physiology Research Group at King’s College London.
His research addresses how the expression, structure, activity
and location of key ion translocating proteins may influence
the response of the heart to ischemia, hypertophy and heart failure.
Current research focuses on T-type Ca channels in cardiovascular
disease and cell proliferation. He has authored over 230 papers
or abstracts on cellular cardiology.
Professor Shattock is a Fellow of the American Heart Association (FAHA) and a Fellow of the European Society of Cardiology (FESC) He is on the Editorial Board and reviewing panel of numerous cardiology and physiology journals. He is, or has been, on the advisory board for a number of major pharmaceutical companies including Hoffman La Roche, Servier and Boehringer-Ingelheim and has advised the Medicines and Healthcare Products Regulatory Agency (MHRA), Wellcome Trust and MRC. He is currently serving on the Project Grants Committee of the British Heart Foundation.